US Patent 7910567 Opticin nucleic acid administration reduces blood vessel formation
Patent 7910567 was granted and assigned to The University of Manchester on March, 2011 by the United States Patent and Trademark Office.
All edits
Edits on 27 Nov, 2023
Golden AI
Edits made to:
Article (+598 characters)
Article
Patent abstract
The invention relates to the use of an agent that promotes class III SLRP activity in the manufacture of a medicament for the inhibition of blood vessel formation. In addition the invention relates to the use of an agent that promotes class III SLRP activity in the manufacture of a medicament for the prevention and/or treatment of conditions characterized by excessive activity and/or migration of monocytes and/or macrophages. Suitable agents may include class III SLRPs such as opticin. Methods of treatment using agents able to promote class III SLRP activity are also provided.
Edits on 15 Jul, 2023
Golden AI
Edits made to:
Infobox (+1/-1 properties)
US Patent 07910567 Opticin nucleic acid administration reduces blood vessel formation US Patent 7910567 Opticin nucleic acid administration reduces blood vessel formation
Infobox
Patent Number
0791056700
Patent Number
791056700
Edits on 25 May, 2023
Golden AI
Edits made to:
Infobox (-1 properties)
Infobox
Official Website
Edits on 29 Apr, 2023
Golden AI
Infobox
Is a
Current Assignee
Patent Jurisdiction
Patent Number
079105670
Date of Patent
March 22, 2011
0Patent Application Number
121017170
Date Filed
April 11, 2008
0Official Website
Patent Primary Examiner
Edits on 24 Sep, 2022
Golden AI
Infobox
Is a
Current Assignee
Patent Jurisdiction
Patent Number
079105670
Date of Patent
March 22, 2011
0Patent Application Number
121017170
Date Filed
April 11, 2008
0Official Website
Patent Primary Examiner
Edits on 4 Jun, 2022
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Website URL
Edits on 7 Dec, 2021
Golden AI
Edits made to:
Infobox (+8 properties)
US Patent 07910567 Opticin nucleic acid administration reduces blood vessel formation
Infobox
Is a
Current assignee
Patent jurisdiction
Patent number
07910567
Date of patent
March 22, 2011
Patent application number
12101717
Date Filed
April 11, 2008
Patent primary examiner
Find more entities like US Patent 7910567 Opticin nucleic acid administration reduces blood vessel formation
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
